Cogent Biosciences (COGT) Cash from Operations: 2017-2024
Historic Cash from Operations for Cogent Biosciences (COGT) over the last 8 years, with Dec 2024 value amounting to -$207.8 million.
- Cogent Biosciences' Cash from Operations fell 121.83% to -$20.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$58.8 million, marking a year-over-year decrease of 63.91%. This contributed to the annual value of -$207.8 million for FY2024, which is 35.26% down from last year.
- Latest data reveals that Cogent Biosciences reported Cash from Operations of -$207.8 million as of FY2024, which was down 35.26% from -$153.6 million recorded in FY2023.
- In the past 5 years, Cogent Biosciences' Cash from Operations ranged from a high of -$35.9 million in FY2020 and a low of -$207.8 million during FY2024.
- Over the past 3 years, Cogent Biosciences' median Cash from Operations value was -$153.6 million (recorded in 2023), while the average stood at -$160.0 million.
- In the last 5 years, Cogent Biosciences' Cash from Operations increased by 13.64% in 2020 and then crashed by 101.89% in 2022.
- Over the past 5 years, Cogent Biosciences' Cash from Operations (Yearly) stood at -$35.9 million in 2020, then slumped by 63.91% to -$58.8 million in 2021, then crashed by 101.89% to -$118.6 million in 2022, then dropped by 29.49% to -$153.6 million in 2023, then plummeted by 35.26% to -$207.8 million in 2024.